Genelux Corporation (NASDAQ: GNLX), a late-stage clinical immuno-oncology company, today announced that the first patient has been dosed in the U.S.-based Phase 2 (VIRO-25) trial evaluating ...
Analysis - Breast cancer is the number one cancer among women: more than 2 million cases were diagnosed worldwide in 2022. It is also particularly challenging to treat. Physiologist Anna-Mart ...